Yosef Yarden

List of Publications by Year
in descending order

25 papers	2,933 citations	304743 22 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	5041 citing authors

#	Article	IF	Citations
1	Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models. EMBO Molecular Medicine, 2021, 13, e13144.	6.9	13
2	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	6.3	191
3	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748.	3.7	148
4	Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers, 2020, 12, 2394.	3.7	34
5	Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Molecular Systems Biology, 2020, 16, e9443.	7.2	41
6	Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochemical and Biophysical Research Communications, 2019, 513, 219-225.	2.1	4
7	Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology, 2019, 1904, 11-51.	0.9	25
8	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 2019, 130, 612-624.	8.2	27
9	An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation <scp>EGFR</scp> inhibitors. EMBO Molecular Medicine, 2018, 10, 294-308.	6.9	46
10	A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways. Clinical Cancer Research, 2018, 24, 5610-5621.	7.0	43
11	The short and the long: non-coding RNAs and growth factors in cancer progression. Biochemical Society Transactions, 2017, 45, 51-64.	3.4	24
12	<scp>LIMT</scp> is a novel metastasis inhibiting lnc<scp>RNA</scp> suppressed by <scp>EGF</scp> and downregulated in aggressive breast cancer. EMBO Molecular Medicine, 2016, 8, 1052-1064.	6.9	77
13	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	5.4	56
14	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Human Vaccines and Immunotherapeutics, 2016, 12, 576-592.	3.3	43
15	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell and Developmental Biology, 2016, 50, 164-176.	5.0	31
16	Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling, 2015, 8, ra53.	3.6	33
17	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1815-1820.	7.1	98
18	Epidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration. PLoS ONE, 2013, 8, e80566.	2.5	15

#	ARTICLE	IF	CITATIONS
19	EGR1 and the ERK–ERF axis drive mammary cell migration in response to EGF. FASEB Journal, 2012, 26, 1582-1592.	0.5	88
20	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13252-13257.	7.1	135
21	Roles for Growth Factors in Cancer Progression. Physiology, 2010, 25, 85-101.	3.1	342
22	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	3.6	100
23	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3294-3299.	7.1	161
24	Derailed endocytosis: an emerging feature of cancer. Nature Reviews Cancer, 2008, 8, 835-850.	28.4	652
25	A module of negative feedback regulators defines growth factor signaling. Nature Genetics, 2007, 39, 503-512.	21.4	506